<table width="100%"> <tbody> <tr> <td width="50%"> Issue# 1403 </td> <td width="50%">
June 19, 2009
</td> </tr> </tbody> </table>
<table width="100%"> <tbody> <tr> <td> <font> Ingen Increases Oxyview Inventory to 162,000 Units for Projected Sales Demands </font> </td> </tr> </tbody> </table> YUCAIPA, Calif., June 18, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company increased the first shipment of Oxyview-Nasal Cannula orders from 10,000 to 62,000 units, and increased production inventory for June to 100,000 units for a revenue value of $2.8 million.
The company notified Legend Medical Devices on Wednesday of this week that the first orders will be increased from 10,000 to 62,000 units for the new Oxyview-Nasal Cannula shipment. Bill Liang, President of Legend Medical Devices has agreed to prepare a revised delivery schedule. The company has received partial shipment and will start advertising the new Oxyview-Nasal Cannula next week. The company website will be updated and this new product will be available next week.
In addition, the company has notified their Corona-California based production facility, Accent Plastics Inc. , to produce another 100,000 Oxyview units. The company will produce 30,000 new Oxyview model 203A units for aviation sales and 70,000 Oxyview model 206A. The new model 203A units will provide pilots with valuable and accurate oxygen readings between 0-3 liters/minute. The company is expecting additional orders from their aviation OEM partner, Delta Technology Inc.
"There is documented demand for our Oxyview products. We are working with COPD Digest on a full page color advertisement in their next edition as a part of our ad saturation campaign. Tom Pridonoff, President of Accent Plastics and Bill Liang, President of Legend Medical Devices have been extremely helpful in keeping on track with our upcoming new production order. More important is that we have completed our funding program under the Rule 504 Registration," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
The company filed a Form D registration under Rule-504 on April 6, 2009, and has recently completed the funding program. The company was notified by Worldwide Stock Transfer on Wednesday this week that the 504 registration had reached its limit. There is no longer a 504 registration or issuance of shares under Rule 504 being implemented at this time.
About Oxyview:
Oxyview is a proprietary medical device with U.S. issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, according to the World Health Organization , and another 12 million patients that are undiagnosed in the U.S. COPD is the fifth leading cause of death in the U.S. and there are 600 million COPD patients worldwide where in most cases, COPD is either the first or second leading cause of death in other countries. The majority of COPD patients require continued home oxygen therapy, which includes all of the required equipment supplied by the home (DME) provider. With the new regulations for oxygen reimbursement in the U.S., the home (DME) providers need to cut costs to stay in business. Oxyview provides a substantial savings as a result of decreasing the number of service calls for the home (DME) provider. Oxyview is a pneumatic metering device that displays oxygen flow near the patient. The Oxyview flow meter easily and quickly installs on to the oxygen tubing nearest the patient where oxygen flow matters the most. Without the Oxyview, patients cannot confirm oxygen flow, and as a result there is an increase in anxiety and the patient calls the home (DME) provider with concerns. Oxyview also allows the home (DME) provider to trouble-shoot other equipment problems over the telephone which eliminates an on-site visit with the patient. More important, the Oxyview provides the patient with more assurance that they are receiving adequate and prescribed oxygen flow. The Oxyview cost less than a single service call.
www.ingen-tech.com
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission .
CONTACT: Ingen Technologies, Inc. Chris Wirth 909-790-7180 info@ingen-tech.com www.INGEN-TECH.COM
<table width="100%"> <tbody> <tr> <td width="50%"> INGEN TECHNOLOGIES, INC.
Stock Symbol :: IGNT </td> <td width="50%"> <table> <tbody> <tr> <td> 
</td> <td> E-Mail this Article to a Friend </td> </tr> <tr> <td> 
</td> <td> Print this Article </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table width="100%"> <tbody> <tr> <td> 
</td> <td> INGEN TECHNOLOGIES, INC. ( IGNT ) Ingen, Inc. manufactures medical devices and provides related services for medical and consumer markets primarily in the United States. </td> </tr> <tr> <td> <table> <tbody> <tr> <td> Recent Price </td> <td> $.0098 </td> </tr> <tr> <td> Market Capitalization </td> <td> $24.5M </td> </tr> <tr> <td> Est Float </td> <td> 468M </td> </tr> <tr> <td> Outstanding Shares </td> <td> 2.5B </td> </tr> <tr> <td> Exchange </td> <td> OTCBB </td> </tr> </tbody> </table>
Ingen Technologies, Inc.
35193 Avenue "A"
Suite-C
Yucaipa, CA 92399
Phone: (800) 259-9622
Fax: 800-777-1186
http://www.ingen-tech.com </td> <td> <table width="100%"> <tbody> <tr> <td> Company Highlights </td> </tr> </tbody> </table> Similar Companies in Sector
· Lincare Holdings Inc. (Lincare) is a provider of oxygen and other respiratory therapy services to patients in the home. Lincare?s customers suffer from chronic obstructive pulmonary disease (COPD), such as emphysema, chronic bronchitis or asthma, and require supplemental oxygen or other respiratory therapy services in order to alleviate the symptoms and discomfort of respiratory dysfunction. Lincare primarily provides oxygen and other respiratory therapy services to patients in the home. NASDAQ:LNCR Recent Price: $.22.68
· American Homepatient, Inc. provides home healthcare services and products consisting primarily of respiratory therapy services, home infusion therapy services, and the rental and sale of home medical equipment and home health care supplies. The Company?s services and products are paid for primarily by Medicare, Medicaid, and other third-party payors. OTCBB:AHOM Recent Price: $.210
</td> </tr> </tbody> </table>
<table width="100%"> <tbody> <tr> <td> Current Projects </td> </tr> </tbody> </table> <table width="100%"> <tbody> <tr> <td width="1%"> 
</td> <td width="49%"> Oxyview Reaches Out to Entire COPD Community in the $4 Billion Respiratory Market
Ingen Technologies, Inc. recently announced that Oxyview was published in the March-2009 issue of HomeCare Magazine, and in the Spring-2009 issue of COPD Digest <font> . </font> COPD, chronic obstructive pulmonary disease, was the underlying cause of 718,077 U.S. deaths in 2000-2005, and it was the underlying cause of about 1 in 20 U.S. deaths for 2005 alone. With more than 20 million Americans diagnosed with COPD and another 12 million projected as being undiagnosed, Oxyview has an annual estimated projected revenue of $30M in the USA, and much greater in the global arena with an expected 600M COPD victims worldwide.
</td> <td width="50%"> Ingen is Granted Patent Rights for China in Estimated $200M Market
Ingen Technologies, Inc. has announced that the Chinese State Intellectual Property for the People's Republic of China is prepared to grant patent rights for Oxyview. In China, chronic obstructive pulmonary disease (COPD) in people over the age of 40 is much more prevalent than previously thought, according to researchers in Guangdong. In China, chronic obstructive pulmonary disease (COPD) in people over the age of 40 is much more prevalent than previously thought. According to an estimation by the World Health Organization, COPD ranks first among the burdens of diseases in China and accounts for one million deaths and five million disabilities each year.
</td> </tr> </tbody> </table>
<table width="100%"> <tbody> <tr> <td> Company Overview </td> </tr> </tbody> </table> <table width="100%"> <tbody> <tr> <td> Ingen, Inc <font> . </font> (OTC.PK: IGNT)
Ingen Technologies brings over 20 years of experience and dedication to the design and support of medical devices, Ingen has helped many medical professionals meet clinical and economic objectives.
Ingen has developed medical products that provide a valuable benefit to the patient and cost savings to the insurance companies, Medicare and essentially the tax payer. The medical products provide a focus for the ever-increasing elderly population. These products are superior to any of our competition and they allow for effective medical product availability to seniors.
Ingen?s Mission: Our Commitment to Customers
Ingen is committed to meeting the needs of our customers through ongoing product innovation and support. Ingen distributes its products through a national distributor network domestically and in Canada, Asia and European Communities. Ingen?s commitment to customers continues beyond the sale of our product.
The Beginning
Ingen, originally a privately owned company founded for the purpose of providing medical solutions for our growing healthcare market, is now a publicly traded company and growing medical device manufacturer. In 1999, Ingen founders invested several millions of dollars in the research and development of state-of-the-art respiratory monitoring devices, with a focus on helping patients and preventing unnecessary costs to the healthcare system. With multiple patents, FDA classification and certifications, Ingen is the largest manufacturer of gravity-independent in-line oxygen flow meters, meeting the demand of the growing patient population and service providers. Our products are manufactured in the USA.
Our Capabilities
We are proud of our capabilities in gas flow-meter technology and wireless digital data transfer of gas flow rate processing. Ingen is the first company to patent and develop transducers that detect oxygen flow rate and provide data transfer. This has revolutionized the oxygen therapy market providing user friendly solutions in monitoring oxygen levels and oxygen delivery systems.
Ingen Technologies, Inc. introduces Oxyview® , the World's First Patient In-Line Oxygen Flow-Meter. Another innovative respiratory product manufactured in the USA by Ingen Technologies; providing more confidence and assurance to patients using oxygen. Oxyview® is reusable, requires no batteries, works all the time in any position with all liquid or gas O2 systems, and easily installs anywhere below the cannula nearest the patient where oxygen flow matters the most. Oxygen suppliers and patients will appreciate that Oxyview® prevents many unnecessary service calls.
Ingen Technologies is now offering a quality organic health supplement for patients using home oxygen therapy, and also to anyone else who is interested in healthy life styles. As a part of wellness, we are now offering the new Poga Moonga products. Poga Moonga includes a substance referred to as Moringa, and is extracted from the Moringa Tree. Ingen provides a drink or capsule that is efficiently absorbed by the bodies metabolism.
One bottle is 25.35 Ounces. The instructions say to take 1-3 oz daily, therefore one bottle should last between 8-25 days. A purchase includes 4 bottles or 1-3 months supply depending upon use.
Author Sanford Holst in ?Moringa, Nature?s Medicine Cabinet,? writes,
"... it is said the Moringa tree prevent 300 diseases. Ancient Roman, Greek and Egyptian civilizations used...the (Moringa Tree)...It is best known as an excellent source of nutrition and a natural energy booster. Loaded with nutrients, vitamins and amino acids, it replenishes your body and provides what you need to through a hectic weekday or active weekend..." It produces long-lasting energy without hyperactivity...a nerve system at rest...a blood system not under pressure...a gland and hormone system in balance."
An L.A. Times article said,
Scientifically speaking, Moringa sounds like magic. It can rebuild weak bones, enrich anemic blood and enable a malnourished mother to nurse her staving baby. Doctors use it to treat diabetes in West Africa and high blood pressure in India...And, it?s not only good for you, it?s delicious." Mark Fritz, L.A. Times.
Perhaps the most remarkable thing about the Moringa is that it has such incredible health benefits over a wide-range of health issues. Here are but a few:
- NUTRITION AND ENERGY BOOST
While most people notice an energy boost right away, the nutritional results with undernourished people is staggering,(See <font> www.treesforlife.org </font> for studies). - DETOXIFICATION
In vitro studies show the Moringa?s ability to remove putrid waste from water. This is important for the planet. Over 6 million children are believed to die each year from infections caused by unclean water. It helps our bodies detoxify in much the same way. - ANTIBIOTIC
Moringa works as a gentle, natural antibiotic,
See Eilert, U.,B. Wolters and A. Nahrstedt. ?The antibiotic principle of seeds of Moringa oleifera and Moringa stenopetala.? Journal of Medicinal Plant Research, 42, pp 55-61. 1981 - SKIN TREATMENT
And, like Aloe Vera, Moringa is believed to have great healing benefits for the skin. Most of the research is on topical applications, but the healing properties would extend to the body itself. - ANTI-INFLAMMATORY
Indian traditional medicines have long used the Moringa in treating the body?s inflammation. See, Udupa, S.L., A.L. Udupa and D.R. Kulkarni, ?Studies on the anti-inflammatory and wound healing properties of Moringa oleifera and Aegle marmelos. Fitoterapia 65(2) pp 119-123. - ULCERS
The anti-ulcer effect of Moringa was reported in 1995 in Phytotherapy research. An extract was taken from dried leaves and showed an impressive ability to heal ulcers in lab animals. Holst, p17. - DIABETES
An extract from the Moringa leaf has been shown to be effective in lowering blood sugar levels with a space of 3 hours. Holst, pp17-18. - SLEEP
The leaf of the Moringa has been shown to aid in a calmer nervous system providing an improving in sleep. Holst, p18
In short some studies have proved Moringa leaves effective for treating,
- Blood pressure
- Diabetes
- Colitis and Diarrhea
- Used as a diuretic
- Headache
- Glandular swelling
- Skin antiseptic
- Fevers
Seeds are used for,
- Fevers
- Tumors
- Rheumatism
- Skin diseases
- Prostate and bladder issues
Leadership
<table width="600"> <tbody> <tr> <td width="160"> Scott R. Sand
</td> <td width="10">
</td> <td width="430"> Chief Executive Officer and Chairman of the Board
</td> </tr> <tr> <td> Thomas J. Neavitt
</td> <td>
</td> <td> Chief Financial Officer
</td> </tr> <tr> <td> J.R. Marple
</td> <td>
</td> <td> Senior Accountant
</td> </tr> <tr> <td> Ron Mitchell
</td> <td>
</td> <td> Certified Public Accountant
</td> </tr> <tr> <td> William Denney
</td> <td>
</td> <td> Auditor- Child, Van Wagoner and Bradshaw LLC
</td> </tr> <tr> <td> Christopher A. Wirth
</td> <td>
</td> <td> Chief Operations Officer & Director
</td> </tr> <tr> <td> Bradley C. Klearman
</td> <td>
</td> <td> Director and EVP of Sales & Distribution
</td> </tr> <tr> <td> David Wald
</td> <td>
</td> <td> Office Manager
</td> </tr> <tr> <td> John Finazzo, MD
</td> <td>
</td> <td> Director and Chairman of the Medical Advisory Board
</td> </tr> <tr> <td> Stephen O?Hara, MD
</td> <td>
</td> <td> Director and Member of the Medical Advisory Board
</td> </tr> <tr> <td> Peter Wilke
</td> <td>
</td> <td> Attorney
</td> </tr> <tr> <td> Donn Harms
</td> <td>
</td> <td> Patent Attorney
</td> </tr> <tr> <td> Robert H. Sand
</td> <td>
</td> <td> Chief Manufacturing Engineer
</td> </tr> <tr> <td> Richard Campbell
</td> <td>
</td> <td> Product Design & Engineering
</td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
<table width="100%"> <tbody> <tr> <td> Market Snapshot </td> </tr> </tbody> </table> <table width="100%"> <tbody> <tr> <td> 
</td> </tr> </tbody> </table>
<table width="100%"> <tbody> <tr> <td> News </td> </tr> </tbody> </table> <table width="100%"> <tbody> <tr> <td> </td> </tr> </tbody> </table>
$0.0 (06/09/09)
